CytoDyn Inc. (CYDY)
USD 0.23
(-1.61%)
USD 0.23
(-1.61%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 18.05 Million USD | -55.3% |
| 2023 | 40.4 Million USD | -43.99% |
| 2022 | 72.12 Million USD | -23.71% |
| 2021 | 94.54 Million USD | 26.66% |
| 2020 | 74.64 Million USD | 33.65% |
| 2019 | 55.85 Million USD | 21.63% |
| 2018 | 45.91 Million USD | 68.0% |
| 2017 | 27.33 Million USD | 29.08% |
| 2016 | 21.17 Million USD | 8.06% |
| 2015 | 19.59 Million USD | 141.54% |
| 2014 | 8.11 Million USD | 1.5% |
| 2013 | 7.99 Million USD | 7.21% |
| 2012 | 7.45 Million USD | 101.6% |
| 2011 | 3.69 Million USD | 0.67% |
| 2010 | 3.67 Million USD | 96.52% |
| 2009 | 1.86 Million USD | 52.13% |
| 2008 | 1.22 Million USD | -50.15% |
| 2007 | 2.46 Million USD | 108.91% |
| 2006 | 1.18 Million USD | 52.22% |
| 2005 | 775.18 Thousand USD | 116.86% |
| 2004 | 357.45 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.39 Million USD | -26.32% |
| 2024 FY | 18.02 Million USD | -55.37% |
| 2024 Q4 | 6.63 Million USD | 94.2% |
| 2024 Q1 | 4.61 Million USD | 22.01% |
| 2024 Q3 | 3.41 Million USD | 0.47% |
| 2023 Q1 | 9.71 Million USD | 74.74% |
| 2023 FY | 40.4 Million USD | -43.99% |
| 2023 Q3 | 3.92 Million USD | -83.07% |
| 2023 Q4 | 3.78 Million USD | -3.6% |
| 2023 Q2 | 23.16 Million USD | 138.5% |
| 2022 Q1 | 21.67 Million USD | -8.29% |
| 2022 FY | 72.12 Million USD | -23.71% |
| 2022 Q4 | 5.55 Million USD | -71.35% |
| 2022 Q3 | 19.39 Million USD | -23.92% |
| 2022 Q2 | 25.49 Million USD | 17.61% |
| 2021 Q4 | 23.63 Million USD | 13.99% |
| 2021 Q1 | 25.56 Million USD | -8.09% |
| 2021 Q2 | 24.5 Million USD | -4.17% |
| 2021 FY | 94.54 Million USD | 26.66% |
| 2021 Q3 | 20.73 Million USD | -15.37% |
| 2020 Q1 | 12.63 Million USD | -8.49% |
| 2020 Q3 | 22.07 Million USD | 82.12% |
| 2020 FY | 74.64 Million USD | 33.65% |
| 2020 Q4 | 27.81 Million USD | 26.02% |
| 2020 Q2 | 12.12 Million USD | -4.05% |
| 2019 Q2 | 15.68 Million USD | 16.3% |
| 2019 Q1 | 13.48 Million USD | 20.47% |
| 2019 Q3 | 12.87 Million USD | -17.95% |
| 2019 Q4 | 13.8 Million USD | 7.25% |
| 2019 FY | 55.85 Million USD | 21.63% |
| 2018 Q2 | 10.77 Million USD | 9.87% |
| 2018 FY | 45.91 Million USD | 68.0% |
| 2018 Q1 | 9.8 Million USD | 25.72% |
| 2018 Q3 | 14.14 Million USD | 31.23% |
| 2018 Q4 | 11.19 Million USD | -20.82% |
| 2017 FY | 27.33 Million USD | 29.08% |
| 2017 Q2 | 6.15 Million USD | 14.89% |
| 2017 Q3 | 8.01 Million USD | 30.23% |
| 2017 Q4 | 7.8 Million USD | -2.69% |
| 2017 Q1 | 5.35 Million USD | -18.51% |
| 2016 Q1 | 6.65 Million USD | -35.73% |
| 2016 FY | 21.17 Million USD | 8.06% |
| 2016 Q2 | 2.89 Million USD | -56.53% |
| 2016 Q4 | 6.57 Million USD | 30.22% |
| 2016 Q3 | 5.04 Million USD | 74.48% |
| 2015 Q4 | 10.35 Million USD | 214.6% |
| 2015 Q1 | 2.95 Million USD | 12.1% |
| 2015 Q3 | 3.29 Million USD | 10.05% |
| 2015 FY | 19.59 Million USD | 141.54% |
| 2015 Q2 | 2.99 Million USD | 1.26% |
| 2014 Q1 | 1 Million USD | -47.73% |
| 2014 Q4 | 2.63 Million USD | -8.34% |
| 2014 Q3 | 2.87 Million USD | 79.62% |
| 2014 FY | 8.11 Million USD | 1.5% |
| 2014 Q2 | 1.6 Million USD | 59.94% |
| 2013 Q4 | 1.91 Million USD | 18.0% |
| 2013 FY | 7.99 Million USD | 7.21% |
| 2013 Q3 | 1.62 Million USD | -1.27% |
| 2013 Q2 | 1.64 Million USD | -41.56% |
| 2013 Q1 | 2.81 Million USD | -17.05% |
| 2012 Q1 | 1.15 Million USD | 5.28% |
| 2012 FY | 7.45 Million USD | 101.6% |
| 2012 Q4 | 3.39 Million USD | 139.61% |
| 2012 Q3 | 1.41 Million USD | -5.15% |
| 2012 Q2 | 1.49 Million USD | 28.76% |
| 2011 FY | 3.69 Million USD | 0.67% |
| 2011 Q2 | 1.05 Million USD | 78.48% |
| 2011 Q3 | 1.06 Million USD | 1.52% |
| 2011 Q4 | 1.1 Million USD | 3.0% |
| 2011 Q1 | 589.66 Thousand USD | -70.46% |
| 2010 Q4 | 1.99 Million USD | 179.82% |
| 2010 Q1 | 275.53 Thousand USD | -30.9% |
| 2010 Q2 | 688.52 Thousand USD | 149.88% |
| 2010 Q3 | 713.34 Thousand USD | 3.61% |
| 2010 FY | 3.67 Million USD | 96.52% |
| 2009 FY | 1.86 Million USD | 52.13% |
| 2009 Q1 | 552.44 Thousand USD | -8.34% |
| 2009 Q3 | 272.15 Thousand USD | -57.86% |
| 2009 Q4 | 398.77 Thousand USD | 46.52% |
| 2009 Q2 | 645.87 Thousand USD | 16.91% |
| 2008 Q2 | 247.48 Thousand USD | 10.59% |
| 2008 Q3 | 154.16 Thousand USD | -37.71% |
| 2008 Q4 | 602.7 Thousand USD | 290.96% |
| 2008 FY | 1.22 Million USD | -50.15% |
| 2008 Q1 | 223.78 Thousand USD | -57.74% |
| 2007 Q4 | 529.52 Thousand USD | -4.03% |
| 2007 FY | 2.46 Million USD | 108.91% |
| 2007 Q2 | 682.07 Thousand USD | 23.61% |
| 2007 Q1 | 551.79 Thousand USD | -28.73% |
| 2007 Q3 | 551.73 Thousand USD | -19.11% |
| 2006 FY | 1.18 Million USD | 52.22% |
| 2006 Q3 | 255.07 Thousand USD | 206.73% |
| 2006 Q2 | 83.16 Thousand USD | 23.12% |
| 2006 Q1 | 67.54 Thousand USD | -14.41% |
| 2006 Q4 | 774.23 Thousand USD | 203.53% |
| 2005 Q2 | 123.32 Thousand USD | 2.18% |
| 2005 Q1 | 120.7 Thousand USD | -28.38% |
| 2005 FY | 775.18 Thousand USD | 116.86% |
| 2005 Q3 | 452.23 Thousand USD | 266.69% |
| 2005 Q4 | 78.91 Thousand USD | -82.55% |
| 2004 Q1 | 1828.00 USD | 0.0% |
| 2004 Q2 | 58.12 Thousand USD | 3079.81% |
| 2004 FY | 357.45 Thousand USD | 0.0% |
| 2004 Q3 | 128.99 Thousand USD | 121.92% |
| 2004 Q4 | 168.52 Thousand USD | 30.64% |
| 2003 Q1 | 3098.00 USD | 0.0% |
| 2003 Q2 | 2118.00 USD | -31.63% |
| 2003 Q3 | 1584.00 USD | -25.21% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -1252.223% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -258.148% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 38.896% |
| Nascent Biotech, Inc. | 2.22 Million USD | -709.82% |
| Rebus Holdings, Inc. | 664 Thousand USD | -2619.578% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 51.53% |
| Qrons Inc. | 643.67 Thousand USD | -2705.444% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -4535.415% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 68.562% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -4246.309% |
| Skye Bioscience, Inc. | 13.54 Million USD | -33.293% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 79.192% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -267.188% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -6799.582% |
| SQZ Biotechnologies Company | 85.61 Million USD | 78.909% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -519.223% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1102.344% |
| Mesoblast Limited | 5.9 Million USD | -205.964% |
| Marizyme, Inc. | 19.23 Million USD | 6.143% |
| Genus plc | 147.7 Million USD | 87.774% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -105.69% |
| Pharming Group N.V. | 225.49 Million USD | 91.992% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -781.435% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1246.06% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -116.549% |
| ContraFect Corporation | 56.88 Million USD | 68.257% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -309.602% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1121.165% |
| IMV Inc. | 37.7 Million USD | 52.113% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -547.157% |
| MultiCell Technologies, Inc. | 567.42 USD | -3182375.063% |
| ONE Bio Corp. | 6.44 Million USD | -180.234% |
| Accustem Sciences Inc. | 3.74 Million USD | -382.007% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 78.989% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -3294.603% |
| Q BioMed Inc. | 3.43 Million USD | -425.457% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 26.935% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -587.264% |
| Biomind Labs Inc. | 994.18 Thousand USD | -1716.368% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 81.82% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -926.21% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -168.8% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -868.585% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 72332.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -12.79% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -884.036% |
| GB Sciences, Inc. | 1.42 Million USD | -1171.234% |
| Alpha Cognition Inc. | 9.7 Million USD | -86.058% |
| HST Global, Inc. | 140.9 Thousand USD | -12715.545% |
| CSL Limited | 3.44 Billion USD | 99.476% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -1505.284% |
| Halberd Corporation | 74.84 Thousand USD | -24028.163% |
| Enzolytics Inc. | 2.17 Million USD | -728.536% |
| Agentix Corp. | 1.37 Million USD | -1216.415% |
| Resverlogix Corp. | 12.71 Million USD | -42.055% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -394.644% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 98.822% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -1629.693% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -650.873% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -1043.378% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -430.341% |
| AVAX Technologies, Inc. | 7.31 Million USD | -147.023% |
| Zenith Capital Corp. | 8.94 Million USD | -101.923% |
| Genscript Biotech Corporation | 825.34 Million USD | 97.812% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -103556.507% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -635.465% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -10428.894% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -840.077% |
| Kadimastem Ltd | 2.41 Million USD | -649.26% |
| Helix BioMedix, Inc. | 1.97 Million USD | -815.704% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -66.173% |
| BioStem Technologies, Inc. | 22.97 Million USD | 21.401% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -9850.134% |
| LadRx Corporation | 3.81 Million USD | -373.741% |
| Cell Source, Inc. | 4.32 Million USD | -317.493% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1855.366% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1855.366% |
| NovAccess Global Inc. | 2.46 Million USD | -632.053% |
| Affymax, Inc. | 39.38 Million USD | 54.151% |
| Itoco Inc. | 919.14 Thousand USD | -1864.656% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -326.056% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -1513.762% |
| Mobile Lads Corp. | 554.54 Thousand USD | -3156.357% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -71646.99% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -8105.273% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -1171.876% |
| SYBLEU INC | 160.87 Thousand USD | -11124.794% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -894.208% |
| International Stem Cell Corporation | 5.27 Million USD | -242.592% |
| Bioxytran, Inc. | 3.82 Million USD | -372.704% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -34203.408% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -88667.635% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 50.207% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -1016.069% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -2354.083% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -480.456% |
| Neutra Corp. | 243.82 Thousand USD | -7306.253% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -3.443% |
| PureTech Health plc | 144.59 Million USD | 87.511% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 11.869% |
| IXICO plc | 4.7 Million USD | -283.641% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -105.275% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 84.664% |
| CSL Limited | 3.89 Billion USD | 99.536% |
| Cellectis S.A. | 97.32 Million USD | 81.445% |